Dentsu Partners with Adobe to Introduce Adobe GenStudio dentsu+
NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Dentsu, in partnership with Adobe, today announced Adobe GenStudio dentsu+, an innovative, generative AI-powered, integrated marketing ecosystem for brands. The culmination of a decade-long relationship, Adobe GenStudio dentsu+ combines Adobe's new, leading Content Supply Chain solution suite, GenStudio, with the power of dentsu's proprietary integrated services, technology and audience intelligence. Underpinned by dentsu's Merkury, the industry's leading data and identity platform, the offering gives marketers the power to efficiently reach and engage audiences in a highly scaled and personalized manner, driving more in-the-moment experiences and bringing consumers even closer to the brand.
Adobe's GenStudio solution brings together applications across Adobe Experience Cloud and Adobe Creative Cloud—including Adobe Experience Manager, Adobe Express, Adobe GenStudio for Performance Marketing and Adobe Workfront, as well as on-brand generative AI capabilities with Firefly Services and Custom Models—all into one combined ecosystem for helping brands plan, create, manage, activate and measure content at scale. It enables marketing teams to create the experiences required to drive impactful, personalized marketing campaigns. And by integrating with dentsu's own audience intelligence, creative insights and translation capabilities, Adobe GenStudio dentsu+ enhances Adobe's suite of services to deliver impactful experiences for clients.
Adobe GenStudio dentsu+ delivers on the combined power of creative, production, media, and digital experience, leveraging dentsu's unique Merkury data sources. The solution sets a new benchmark for how marketers can fully utilize Adobe, while effectively targeting millions of customers and prospects in a way that speaks to them individually—not only delivering on customer expectations but also bringing them closer to the brand through each interaction. In addition, marketers can now gain a single view across campaign management, content supply chain, and identity mapping, underpinned by dentsu proprietary AI solutions, creating opportunity to lower waste, increase efficiency, and drive engagement.
'Adobe GenStudio dentsu+ is a direct response to CMOs demanding holistic marketing platforms to drive new growth and provides integrated marketing technology and services that can supercharge business transformation,' said Abbey Klaassen, Global Brand President, Dentsu Creative & CEO, Dentsu Creative US. 'It's testament to dentsu's deep relationship with Adobe that we'll be able to bring this industry-first solution to market to enable brands to stand out from the sea of sameness and build a competitive advantage. As one of the first users ourselves, we're already seeing synergies created with our other products and services, and expect clients will have the same experience, finding opportunities both for their in-house teams and their work with their agencies.'
'Marketers are operating in an environment now where the need for personalized and performant content is outstripping available resources, a challenge that Adobe GenStudio addresses by optimizing a brand's content supply chain,' said Brent Rudewick, Vice President, Adobe GenStudio and Workfront, Adobe. 'Adobe and dentsu have a longstanding partnership that focuses on delivering tailored solutions for brands. Now, combining GenStudio with dentsu's audience intelligence and consultancy, we have the opportunity to activate generative AI for different teams, reshape longstanding workflows around content production and deliver on-brand performance at scale.'
For brands looking to fully utilize Adobe's tech stack to gain competitive advantage and deliver on customer expectations, while delivering omnipresent brand experiences with zero creative waste, Adobe GenStudio dentsu+ truly leverages the power of dentsu's entire breadth of capabilities. Transformative creativity from Dentsu Creative enables emotional brand resonance across the entire content lifecycle. Experience enablement and optimization from Merkle maximizes martech investments. Next-generation media effectiveness from Carat, iProspect and dentsu X leverages a 100% addressable, 100% shoppable, and 100% accountable media mix. Meanwhile, dentsu's global production powerhouse, Tag, allows for adaptive, intelligent, connected content production, translation, and versioning at scale.
'Bringing together these innovative capabilities for the first time creates total business impact for our clients. What we have built alongside Adobe is an adaptive, end-to-end content supply chain solution, in which we can create always-on, always-ready experiences with the least amount of waste,' commented Shirli Zelcer, Chief Data & Technology Officer, dentsu. 'Brands no longer have to try and piece together disparate systems and data—they can do it all in one place. Adobe GenStudio dentsu+ will not only drive better outcomes, but it will save time and add scale to marketing teams already under considerable pressure.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
Vaxart Announces Adjournment of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ('Vaxart' or the 'Company') announced today that its 2025 annual meeting of stockholders (the 'Annual Meeting') has been adjourned to Friday, June 13, 2025 at 8:30 a.m. Pacific Time with respect to all proposals described in Vaxart's definitive proxy statement filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 10, 2025 (the 'Proxy Statement'). 'In recent days, we have engaged in constructive conversations with some of our larger stockholders to address their questions and concerns regarding the reverse stock split proposal,' said Steven Lo, Chief Executive Officer of Vaxart. 'I am pleased to report that following these discussions, many have indicated their intention to vote in favor of Proposal No. 2. This shift underscores the increasing understanding of the necessity of this proposal to ensure our continued Nasdaq listing as we focus on our exciting upcoming milestones.' The reconvened Annual Meeting will be held in a virtual-only format, which can be accessed by visiting and entering the 16‐digit control number included in your Notice of Internet Availability of Proxy Materials, on your proxy card or in the instructions that accompanied your proxy materials. During the adjournment, Vaxart continues to solicit votes from its stockholders with respect to all proposals set forth in the Proxy Statement. Proxies previously submitted with respect to the Annual Meeting will be voted on all applicable proposals at the adjourned Annual Meeting unless properly revoked in accordance with the procedures described in the Proxy Statement, and stockholders who have previously submitted a proxy or otherwise voted need not take any action. Both leading independent proxy advisory firms, Institutional Shareholder Services ('ISS') and Glass Lewis, recommend that stockholders support Proposal No. 2. A message from Dr. Sean Tucker, Founder and Chief Scientific Officer, and a fact sheet that addresses several misconceptions about the proposed reverse stock split can be found on Vaxart's investor relations website at Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 12, 2025. The Company also reminds those who have previously voted against Proposal No. 2 that they can change their vote in favor of the proposal. If you have any questions or need assistance with voting, please contact Vaxart's proxy solicitation firm: Campaign Management, LLCToll-Free: 1-855-264-1527Email: info@ About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act') and Section 21E of the Securities Exchange Act of 1934, as amended (the 'Exchange Act'), which are subject to the 'safe harbor' created by those sections, concerning our business, operations, and financial performance and condition as well as the annual meeting of stockholders, our plans, objectives, and expectations for business operations, funding, and financial performance and condition. Any statements contained herein that are not of historical facts may be deemed to be forward-looking statements. You can identify these statements by words such as 'anticipate,' 'assume,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'should,' 'will,' 'would,' and other similar expressions that are predictions of or indicate future events and future trends. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about our business and the industry in which we operate and management's beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this press release may turn out to be inaccurate. Factors that could materially affect our business operations and financial performance and condition include, but are not limited to, those risks and uncertainties described under 'Item 1A - Risk Factors' in our Annual Report on Form 10-K for the year ended December 31, 2024 and any risk factors disclosed in any subsequent Quarterly Reports on Form 10-Q. You are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on the forward-looking statements. The forward-looking statements are based on information available to us as of the date of this press release. Unless required by law, we do not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this press release. Participants in the SolicitationThe Company and its directors, executive officers, and certain employees and other persons may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the business to be conducted at the annual meeting of stockholders. Investors and security holders may obtain more detailed information regarding the names, affiliations, and interests of the Company's directors and executive officers in the definitive proxy statement filed in connection with the annual meeting of stockholders as well as the Company's other filings with the U.S. Securities and Exchange Commission (the 'SEC'), all of which may be obtained free of charge at the website maintained by the SEC at Contact Vaxart Media and Investor RelationsMatt SteinbergFINN PartnersIR@ 871-8481 This press release was published by a CLEAR® Verified in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on June 2, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to purchase an aggregate of 137,400 shares of the Company's common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual's entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual's entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $1.28 per share, which is equal to the closing price of Zentalis' common stock on The Nasdaq Global Market on the date of grant. The stock options have a 10-year term and will vest over four years, with 25% of the options vesting on the first anniversary of the vesting commencement date and the remaining 75% of the options vesting in equal monthly installments over the three years thereafter. Vesting of the stock options is subject to the employees' continued service to Zentalis on each vesting date. About Zentalis PharmaceuticalsZentalis® Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1+ platinum-resistant ovarian cancer (PROC). Azenosertib is being evaluated as a monotherapy and in combination across multiple tumor types in clinical trials and has broad franchise potential. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types. The Company is also leveraging its extensive experience and capabilities to translate its science to advance research on additional areas of opportunity for azenosertib outside PROC. Zentalis has operations in San Diego. For more information, please visit Follow Zentalis on X/Twitter at @ZentalisP and on LinkedIn at Contact:Aron Feingold, VP, IR & Corp Commsir@
Yahoo
26 minutes ago
- Yahoo
Kilwins Introduces Chocolate-on-the-Inside Waffle Cones, Taking Ice Cream to the Next Level
Enjoy the Upgrade for Free on National Chocolate Ice Cream Day – June 7, 2025 New Kilwins Chocolate-on-the-Inside Waffle Cones Kilwins Chocolate-on-the-Inside Fresh-Baked Waffle Cones Petoskey, MI, June 02, 2025 (GLOBE NEWSWIRE) -- Kilwins, a renowned franchisor of hand-crafted chocolates, fudge, and super-premium ice cream, is thrilled to introduce its latest innovation: Chocolate-on-the-Inside Waffle Cones. This uniquely Kilwins experience brings together the brand's signature Heritage Dark Chocolate and freshly made, warm waffle cones, creating an indulgent treat that takes enjoyment to a whole new level. Customers can try the Chocolate-on-the-Inside upgrade for free with the purchase of a waffle cone or waffle bowl of Kilwins Original Recipe Ice Cream on National Chocolate Ice Cream Day, which is Saturday, June 7. Participating locations are listed here: The Chocolate-on-the-Inside Waffle Cone is freshly coated in-store while you watch, using Kilwins' exclusive Chocolate on-the-Inside Fountain, which lines the inside of each waffle cone with warm, velvety Kilwins Heritage Chocolate. This exceptional process, which took years to perfect, ensures that every bite delivers the perfect balance of rich, smooth chocolate and crisp, buttery waffle cone – ready to be filled with your favorite flavor of Kilwins Original Recipe Ice Cream! 'For over 75 years, Kilwins has been dedicated to crafting the finest confections and ice cream, and we're excited to introduce a new way for customers to enjoy our Heritage Chocolate,' said Joe Audia, vice president and general manager of Kilwins Quality Confections. 'This new offering combines the warmth of tradition with a fresh, interactive experience—something truly special for chocolate and ice cream lovers alike.' What Makes Kilwins Chocolate-on-the-Inside Waffle Cones Special? Freshly made in-store: Customers can watch chocolate cascade through the Chocolate-on-the-Inside Fountain as their waffle cone is coated-to-order with warm, melted Kilwins Heritage Chocolate. Premium Kilwins Heritage Chocolate: The same rich, Fair Trade Certified™ chocolate, made exclusively in the U.S.A. by Kilwins for Kilwins stores, is used in the fountain as well as in Kilwins' signature chocolates and confections. Unique flavor and texture experience: The chocolate remains slightly liquid inside the cone, creating a delightful contrast with Kilwins' Original Recipe Ice Cream. Several Kilwins locations across the country are now offering this exciting new addition and participating in this promotion, giving customers a delicious new way to enjoy their favorite ice cream flavors. Whether paired with Kilwins' signature Sea-Salt Caramel, Toasted Coconut, or classic Old Fashioned Vanilla Ice Cream, the Chocolate-on-the-Inside Waffle Cone is sure to delight fans of all ages. Visit to learn more and find a list of participating stores! ### About Kilwins: Kilwins is renowned for its hand-crafted chocolates, creamy fudge, caramel apples, brittle, and super-premium ice cream, all made with the finest ingredients. Kilwins has been making people happy since 1947, providing customers with warm, friendly service and a nostalgic confectionery experience. Customers can enjoy watching fudge being paddled on a marble table and caramel cooking in a copper kettle, all in an open kitchen setting. The brand has 170+ locations and growing, and has earned industry recognition, ranking #1 in category in Entrepreneur magazine's Franchise 500® for 9 consecutive years. Kilwins is truly "Sweet in every Sense since 1947®." For more information about Kilwins, visit To learn more about franchising opportunities, visit Attachments New Kilwins Chocolate-on-the-Inside Waffle Cones Kilwins Chocolate-on-the-Inside Fresh-Baked Waffle Cones CONTACT: Renee Cossman renee@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
